{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:23Z","timestamp":1787162603918,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"\u201cResearch Center of the Center for Female Scientific and Medical Colleges,\u201d"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jchromb.2016.05.033","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T03:15:13Z","timestamp":1464491713000},"page":"100-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC\u2013MS\/MS: Application to pharmacokinetic interaction studies"],"prefix":"10.1016","volume":"1028","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-9012","authenticated-orcid":false,"given":"Hadir M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah Z.","family":"Alzoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen M.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jchromb.2016.05.033_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biopha.2009.06.010","article-title":"Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects","volume":"64","author":"Shen","year":"2010","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcp.2014.01.010","article-title":"Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidinephosphorylase expression in human non-small-cell lung cancer cells","volume":"88","author":"Ko","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbrc.2014.11.116","article-title":"Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells","volume":"456","author":"Ko","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2011.01.016","article-title":"Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes","volume":"74","author":"Song","year":"2011","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid tumour-targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0040","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.clinthera.2009.11.008","article-title":"Clinically significant drug\u2013drug interactions between oral anticancer agents and nonanticancer agents: a delphi survey of oncology pharmacists","volume":"31","author":"Chan","year":"2009","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jchromb.2016.05.033_bib0050","first-page":"487","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Mir","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jchromb.2016.05.033_bib0055","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.lungcan.2007.02.011","article-title":"Significant drug interaction: phenytoin toxicity due to erlotinib","volume":"57","author":"Grenader","year":"2007","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.jchromb.2016.05.033_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CLC.2008.n.036","article-title":"Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin","volume":"9","author":"Veeraputhiran","year":"2008","journal-title":"Clin. Lung Cancer"},{"issue":"17","key":"10.1016\/j.jchromb.2016.05.033_bib0065","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2146\/ajhp090202","article-title":"Elevated international normalized ratio associated with concomitant warfarin and erlotinib","volume":"67","author":"Thomas","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"10.1016\/j.jchromb.2016.05.033_bib0070","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/dmd.107.018598","article-title":"Role of human pregnane X receptor in tamoxifen and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells","volume":"36","author":"Sane","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0075","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.talanta.2015.07.078","article-title":"A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines","volume":"144","author":"Garrido-Cano","year":"2015","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchromb.2013.03.017","article-title":"An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients","volume":"928","author":"Zheng","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchromb.2012.02.037","article-title":"HPLC\u2013DAD protein kinase inhibitor analysis in human serum","volume":"893\u2013894","author":"Dziadosz","year":"2012","journal-title":"J. Chromatogr. B"},{"issue":"3","key":"10.1016\/j.jchromb.2016.05.033_bib0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3797\/scipharm.1205-09","article-title":"Simultaneous determination of celecoxib, erlotinib, and its metabolite desmethyl-erlotinib (OSI-420) in rat plasma by liquid chromatography\/tandem mass spectrometry with positive\/negative ion-switching electrospray ionisation","volume":"80","author":"Thappali","year":"2012","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J. Chromatogr. B"},{"issue":"5","key":"10.1016\/j.jchromb.2016.05.033_bib0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/bmc.3357","article-title":"Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography\u2013tandem mass spectrometry and its clinical application","volume":"29","author":"Ishida","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chroma.2012.12.031","article-title":"Liquid chromatography coupled to tandem mass spectrometry and high resolution mass spectrometry as analytical tools to characterize multi-class cytostatic compounds","volume":"1276","author":"G\u00f3mez-Canela","year":"2013","journal-title":"J. Chromatogr. A"},{"issue":"11\u201312","key":"10.1016\/j.jchromb.2016.05.033_bib0110","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jpba.2016.03.013","volume":"124","author":"Maher","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.jchromb.2016.05.033_bib0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.talanta.2011.01.022","article-title":"Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines","volume":"84","author":"Aranda","year":"2011","journal-title":"Talanta"},{"issue":"23","key":"10.1016\/j.jchromb.2016.05.033_bib0125","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09674845.2014.11669960","article-title":"Evaluation of tamoxifen and metabolites by LC-MS\/MS and HPLC methods","volume":"71","author":"Heath","year":"2014","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpba.2012.12.005","article-title":"Sensitive HPLC\u2013PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma","volume":"76","author":"Antunes","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.jchromb.2016.05.033_bib0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0378-4347(95)00530-7","article-title":"Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma","volume":"678","author":"MacCallum","year":"1996","journal-title":"J. Chromatogr. B"},{"issue":"19","key":"10.1016\/j.jchromb.2016.05.033_bib0145","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jchromb.2011.04.011","article-title":"Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"879","author":"Teunissen","year":"2011","journal-title":"J. Chromatogr. B"},{"issue":"24","key":"10.1016\/j.jchromb.2016.05.033_bib0150","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.jchromb.2009.06.029","article-title":"Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"877","author":"Teunissen","year":"2009","journal-title":"J. Chromatogr. B"},{"issue":"27","key":"10.1016\/j.jchromb.2016.05.033_bib0155","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.jchromb.2011.07.036","article-title":"Liquid chromatography\u2013mass spectrometry method for the quantification of tamoxifen and its metabolite 4-hydroxytamoxifen in rat plasma: application to interaction study with biochanin A (an isoflavone)","volume":"879","author":"Singh","year":"2011","journal-title":"J. Chromatogr. B"},{"issue":"3","key":"10.1016\/j.jchromb.2016.05.033_bib0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-013-2346-z","article-title":"Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry","volume":"73","author":"Ng","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.05.033_bib0165","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.talanta.2014.10.040","volume":"132","author":"Antunes","year":"2015","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jpba.2014.07.033","article-title":"An UPLC\u2013MS\/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers","volume":"100","author":"Arellano","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"32","key":"10.1016\/j.jchromb.2016.05.033_bib0175","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1016\/j.jchromb.2010.10.027","article-title":"An ultra performance liquid chromatography\u2013tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4-hydroxylated metabolites in breast cancer patients","volume":"878","author":"Dahmane","year":"2010","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/j.jchromb.2016.05.033_bib0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/2193-1801-2-126","article-title":"Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer","volume":"2","author":"Vardy","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0185","series-title":"Center for Drug Evaluation and Research (CDER): Guidance for Industry on Bioanalytical Method Validation","author":"US Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0190","series-title":"Saudi Arabia","author":"World Health Organization","year":"2016"},{"issue":"8","key":"10.1016\/j.jchromb.2016.05.033_bib0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/00498250210143029","article-title":"Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects","volume":"32","author":"John","year":"2002","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0200","series-title":"Principles, Techniques, and Applications","article-title":"Solid-Phase extraction","author":"Henry","year":"2016"},{"key":"10.1016\/j.jchromb.2016.05.033_bib0205","series-title":"Statistics and Chemometrics for Analytical Chemistry","author":"Miller","year":"2000"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216303464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216303464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T03:30:36Z","timestamp":1572406236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023216303464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":41,"alternative-id":["S1570023216303464"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.05.033","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC\u2013MS\/MS: Application to pharmacokinetic interaction studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}